- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02130414
PK, Safety & Tolerability of CyCol® Versus Sandimmune® in Healthy Subjects (CYC102)
A Multiple Dose, Multi-stage Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Colon Tissue Distribution of Cyclosporine Capsules (CyCol®) Compared to Intravenous Cyclosporine in Healthy Male Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open label, multiple-dose, multi-stage pharmacokinetic (PK) study. A maximum of 40 healthy adult male volunteers aged between 18 and 55 years will be enrolled at a single clinical research unit.
For each CyCol® group dosing will last 7 days, whilst the Sandimmun® IV group will have a single dose over 24 hours.
Single dose pharmacokinetics of different doses of CyCol® will be compared to IV Sandimmun®. In addition colonic tissue concentrations will be compared after multiple doses of CyCol® to a single IV dose of Sandimmun®. Concentrations of unchanged cyclosporine and it's metabolites in the faeces will also be explored.
Stage 1 of the study will investigate the 75mg dose (OD and BID) of CyCol® and IV Sandimmun®. Then dependent on results Stages 2 and 3 will investigate either lower (37.5mg) or higher (150mg) dose levels. The dosing regimens chosen for Stages 2 and 3 will be based upon safety and tolerability, systemic exposure and colonic mucosa tissue concentrations observed at other doses.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male volunteers, between the ages of 18 and 55 years, inclusive.
- Mass Index (BMI) of 18.5 to 30.0 kg/m2, inclusive; and a total body weight >50 kg (110 lbs).
- Subjects capable of providing written consent.
- Subjects willing to use acceptable method of contraception starting from the first dose and continuing for at least 3 months after the last dose of study drug.
- Subjects who are willing and able to comply with scheduled visits, dosing plan, laboratory tests, and other study procedures.
- Subjects must have a regular bowel movement
Exclusion Criteria:
- Any condition possibly affecting drug absorption (eg, gastrectomy).
- A positive urine drug screen.
- History of significant drug abuse
- History of regular alcohol consumption
- Treatment with an investigational drug within 90 days prior to first dose of study medication.
- If considered clinically significant by the Investigator, screening supine blood pressure 140 mm Hg (systolic) or 90 mm Hg (diastolic), on a single measurement (confirmed by a single repeat, if necessary) following at least 5 minutes of rest.
- 12-lead ECG demonstrating QTcF interval >450 msec or a QRS interval >120 msec at Screening.
Use of medications :
- prescription medications (oral and topical) within 14 days prior to first dosing.
- over-the-counter products including herbal and food supplements within 7 days prior to first dose of study medication
- injection or implant of any drug within 3 months prior to first dose of study medication
- Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication.
- Plasma donation within 7 days prior to dosing.
- History of sensitivity to cyclosporine or other related drugs.
- Subjects with evidence of ongoing (active or carrier status) hepatitis B or C, or human immunodeficiency virus (HIV) infection upon serological testing.
- History of latent or active tuberculosis or exposure to endemic areas within 8 weeks prior to Quantiferon test performed at screening.
- Positive Quantiferon test result
- Subjects who have received or are planning to receive any live virus vaccination within 28 days prior to the first dose of study medication, or planning to receive a vaccination during the course of the study.
- Any evidence of active infection or febrile illness within 7 days of the first dose of study medication
- Presence of fever (body temperature >37.6oC) within 2 weeks prior to first dose of study medication.
- Subjects who are unwilling to refrain from consumption of grapefruit or products containing grapefruit juice or grapefruit-related citrus fruits (eg, starfruit, pomelos) from 7 days prior to the first dose of study medication until completion of all study procedures.
- Unwilling or unable to comply with the guidelines described in this protocol, or a reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Sandimmun® IV
Sandimmun® IV 2mg/kg as a 24 hour infusion (2mg/kg/day)
|
2 mg/kg IV
Other Names:
|
EXPERIMENTAL: CyCol® capsules
CyCol®: 75 mg OD & BID for 7 days
|
37.5 mg CyCol® capsules
Other Names:
|
EXPERIMENTAL: CyCol® capsules 37.5 mg
CyCol®: 37.5 mg OD or BID for 7 days
|
37.5 mg CyCol® capsules
Other Names:
|
EXPERIMENTAL: CyCol® capsules, 150 mg
CyCol®: 150 mg OD or BID for 7 days
|
37.5 mg CyCol® capsules
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic variables for cyclosporine (in whole blood)
Time Frame: Day 1 and Day 7
|
Area under the concentration-time curve (AUC) from;
|
Day 1 and Day 7
|
Concentrations (ng/g) of cyclosporine and its metabolites (AM1, AM9, AM4N) in colonic mucosa
Time Frame: Day 2 or Day 7
|
Concentrations (ng/g) of cyclosporine and its metabolites (AM1, AM9, AM4N)in colonic mucosal tissue
|
Day 2 or Day 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability of CyCol
Time Frame: Day 1 to Day 7
|
Percentage of subjects with clinically significant abnormal results
|
Day 1 to Day 7
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Amount of unchanged cyclosporine and its metabolites excreted in faeces
Time Frame: Day 1 through Day 7
|
To evaluate the amount (ng/g) of unchanged cyclosporine and its metabolites (AM1, AM9, AM4N) excreted in the faeces.
|
Day 1 through Day 7
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Sigmoid Pharma, Sigmoid Pharma
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CYC102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on Sandimmun® IV
-
Novartis PharmaceuticalsCompletedLiver TransplantationGermany
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingPostoperative HypothermiaFrance
-
Smiths Medical, ASD, Inc.CompletedPeripheral Intravenous CatheterCanada
-
NovartisCompleted
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedAdvanced Adult Primary Liver Cancer | Localized Resectable Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | Stage A Adult Primary Liver Cancer (BCLC) | Stage B Adult Primary Liver Cancer (BCLC)United States
-
Lazarski UniversityPoznan University of Medical Sciences; Wroclaw Medical University; Medical University...CompletedShock | Emergency Medicine | Cardiopulmonary ArrestPoland
-
Foundation for Innovative New Diagnostics, SwitzerlandCompleted
-
National Taiwan University HospitalMinistry of Science and Technology, Taiwan; TeleflexCompletedVascular Access | Out-of-Hospital Cardiac Arrest | Intraosseous Access | Emergency Medical Service | Intravenous AccessTaiwan
-
Syros PharmaceuticalsSuspendedAcute Promyelocytic LeukemiaUnited States
-
Nantes University HospitalDirection Générale de l'Offre de SoinsCompletedStreptococcus AgalactiaeFrance